摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,5,5-trimethyl-3-hexanol | 66793-72-4

中文名称
——
中文别名
——
英文名称
2,5,5-trimethyl-3-hexanol
英文别名
2,5,5-trimethyl-hexan-3-ol;Isopropyl-neopentyl-carbinol;2,5,5-Trimethylhexan-3-ol
2,5,5-trimethyl-3-hexanol化学式
CAS
66793-72-4
化学式
C9H20O
mdl
——
分子量
144.257
InChiKey
NPUIBFBNZSKEAP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    169.6±8.0 °C(Predicted)
  • 密度:
    0.822±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    10
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    20.2
  • 氢给体数:
    1
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    2,5,5-trimethyl-3-hexanol4-二甲氨基吡啶 、 palladium diacetate 、 N,N'-二环己基碳二亚胺三苯基膦 作用下, 以 三乙胺甲苯 为溶剂, 反应 122.0h, 生成 4-Ethynyl-benzoic acid 1-isopropyl-3,3-dimethyl-butyl ester
    参考文献:
    名称:
    5- [4-(3,3-二甲基丁氧基羰基)苯基] -4-戊酸及其衍生物通过与4'-乙炔基-4-n-丙基双环原苯甲酸酯位点结合,抑制离子型γ-氨基丁酸受体。
    摘要:
    设计,合成并合成了具有酯或醚键的离子型γ-氨基丁酸(GABA)受体的无环非竞争性拮抗剂,并测定了它们对[3H] 4'-乙炔基-4-n-丙基双环原苯甲酸酯的特异性结合的抑制作用( EBOB),一种放射性标记的非竞争性拮抗剂,对大鼠的大脑和家蝇的头膜。发现苯甲酸丁酯类似物5- [4-(3,3-二甲基丁氧基羰基)苯基] -4-戊酸(DBCPP)竞争性抑制大鼠脑膜中[3H] EBOB的结合,IC50为88 nM。由p-取代基赋予的效力按C(三键)C(CH2)2COOH> C(三键)C(CH2)2COOCH3> C(三键)CH> Br的顺序降低。与苯甲酸丁酯相比,戊基苯基醚具有同等效力,而戊酸苯基酯和苄基丁基醚的蓬松度较低。这些化合物通常在家蝇头膜中的活性低于在大鼠脑膜中的活性。在苯甲酸丁酯和两个苄基丁基醚的3,3-二甲基丁基的1位上引入异丙基会导致家蝇GABA受体的效力增加,而在其他化合物相应位置
    DOI:
    10.1016/s0968-0896(00)00009-2
  • 作为产物:
    参考文献:
    名称:
    Whitmore; Forster, Journal of the American Chemical Society, 1942, vol. 64, p. 2967
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION
    申请人:Bonfanti Jean-Francois
    公开号:US20080280881A1
    公开(公告)日:2008-11-13
    The present invention concerns morpholinyl containing benzimidazoles having inhibitory activity on the replication of the respiratory syncytial virus and having the formula a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein G is a direct bond or optionally substituted C 1-10 alkanediyl; R 1 is Ar 1 or a monocyclic or bicyclic heterocycle Q is R 7 , pyrrolidinyl substituted with R 7 , piperidinyl substituted with R 7 or homopiperidinyl substituted with R 7 ; one of R 2a and R 3a is selected from halo, optionally mono- or polysubstituted C 1-6 alkyl, optionally mono- or polysubstituted C 2-6 alkenyl, nitro, hydroxy, Ar 2 , N(R 4a R 4b ), N(R 4a R 4b )sulfonyl, N(R 4a R 4b )carbonyl, C 1-6 alkyloxy, Ar 2 oxy, Ar 2 C 1-6 alkyloxy, carboxyl, C 1-6 alkyloxycarbonyl, or —C(=Z)Ar 2 ; and the other one of R 2a and R 3a is hydrogen; in case R 2a is different from hydrogen then R 2b is hydrogen, C 1-6 alkyl or halogen and R 3b is hydrogen; in case R 3a is different from hydrogen then R 3b is hydrogen, C 1-6 alkyl or halogen and R 2b is hydrogen. It further concerns the preparation thereof and compositions comprising these compounds, as well as the use thereof as a medicine.
    本发明涉及含有吗啡啉基的苯并咪唑,具有对呼吸道合胞病毒复制的抑制活性,其具有以下式子: 其中G为直接键或可选取代的C1-10烷二基;R1为Ar1或单环或双环杂环;Q为R7、用R7取代的吡咯烷基、用R7取代的哌啶基或用R7取代的同型哌啶基;R2a和R3a中的一个选自卤素、可选单或多取代的C1-6烷基、可选单或多取代的C2-6烯基、硝基、羟基、Ar2、N(R4aR4b)、N(R4aR4b)磺酰基、N(R4aR4b)羰基、C1-6烷氧基、Ar2氧基、Ar2C1-6烷氧基、羧基、C1-6烷氧羰基或—C(=Z)Ar2;而R2a和R3a中的另一个为氢;若R2a不为氢,则R2b为氢、C1-6烷基或卤素,而R3b为氢;若R3a不为氢,则R3b为氢、C1-6烷基或卤素,而R2b为氢。 此外,本发明还涉及其制备方法和包含这些化合物的组合物,以及其作为药物的用途。
  • Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication
    申请人:Bonfanti Jean-Francois
    公开号:US20070043022A1
    公开(公告)日:2007-02-22
    The present invention concerns morpholinyl containing benzimidazoles having inhibitory activity on the replication of the respiratory syncytial virus and having the formula a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein G is a direct bond or optionally substituted C 1-10 alkanediyl; R 1 is Ar 1 or a monocyclic or bicyclic heterocycle Q is R 7 , pyrrolidinyl substituted with R 7 , piperidinyl substituted with R 7 or homopiperidinyl substituted with R 7 ; one of R 2a and R 3a is selected from halo, optionally mono- or polysubstituted C 1-6 alkyl, optionally mono- or polysubstituted C 2-6 alkenyl, nitro, hydroxy, Ar 2 , N(R 4a R 4b ) N(R 4a R 4b )sulfonyl, N(R 4a R 4b )carbonyl, C 1-6 alkyloxy, Ar 2 oxy, Ar 2 C 1-6 alkyloxy, carboxyl, C 1-6 alkyloxycarbonyl, or —C(=Z)Ar 2 ; and the other one of R 2a and R 3a is hydrogen; in case R 2a is different from hydrogen then R 2b is hydrogen, C 1-6 alkyl or halogen and R 3b is hydrogen; in case R 3a is different from hydrogen then R 3b is hydrogen, C 1-6 alkyl or halogen and R 2b is hydrogen. It further concerns the preparation thereof and compositions comprising these compounds, as well as the use thereof as a medicine.
    本发明涉及含有morpholinyl的苯并咪唑类化合物,具有抑制呼吸道合胞病毒复制的活性,其具有以下式子:a prodrug,N-oxide,加合盐,季铵盐,金属络合物或其立体化学异构体形式,其中G是直链键或可选取代的C1-10烷二基;R1是Ar1或单环或双环杂环;Q是R7,用R7取代的吡咯烷基,用R7取代的哌啶基或用R7取代的同源哌啶基;R2a和R3a中的一个选自卤素,可选取代的C1-6烷基,可选取代的C2-6烯基,硝基,羟基,Ar2,N(R4aR4b),N(R4aR4b)磺酰基,N(R4aR4b)羰基,C1-6烷氧基,Ar2氧基,Ar2C1-6烷氧基,羧基,C1-6烷氧羰基或-C(=Z)Ar2;R2a和R3a中的另一个是氢;如果R2a与氢不同,则R2b是氢,C1-6烷基或卤素,而R3b是氢;如果R3a与氢不同,则R3b是氢,C1-6烷基或卤素,而R2b是氢。本发明进一步涉及其制备方法和包含这些化合物的组合物,以及将其用作药物的用途。
  • COMPOUNDS AND METHODS OF USE THEREOF
    申请人:Elder Amy
    公开号:US20110144090A1
    公开(公告)日:2011-06-16
    Indole compounds are disclosed. Also disclosed are methods for using the compounds to treat human and animal disease, pharmaceutical compositions of the compounds, and kits including the compounds.
    揭示了吲哚化合物。还揭示了使用该化合物治疗人类和动物疾病的方法,该化合物的药物组成以及包括该化合物的试剂盒。
  • Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus
    申请人:Aicher Thomas Daniel
    公开号:US20100204240A1
    公开(公告)日:2010-08-12
    Provided are compounds of Formula (I): wherein R 2 , R 3 , R 13 , L and D 2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.
    提供的化合物式(I)如下:其中R2、R3、R13、L和D2如规范中所定义,这些化合物可用于治疗和/或预防由于葡萄糖激酶活性不足引起或可以通过激活葡萄糖激酶治疗的疾病或紊乱,包括但不限于糖尿病、糖耐量受损、IFG(空腹血糖受损)和IFG(空腹高血糖),以及本文所讨论的其他疾病和紊乱。
  • Pyridin-2YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus
    申请人:AICHER Thomas Daniel
    公开号:US20120277242A1
    公开(公告)日:2012-11-01
    Provided are compounds of Formula (I): wherein R 2 , R 3 , R 13 , L and D 2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.
    本发明提供了式(I)的化合物:其中R2、R3、R13、L和D2如规范中所定义,它们在治疗和/或预防由葡萄糖激酶活性不足介导的疾病或疾病中有用,或者可以通过激活葡萄糖激酶来治疗,包括但不限于糖尿病、糖耐量受损、IFG(空腹血糖受损)和IFG(空腹高血糖),以及其他疾病和疾病,如在此处所讨论的。
查看更多